Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. Dec. 6, 2018. Bram Zuckerman.

Executive Summary

The first US FDA device advisory panel to address a product on FDA's Breakthrough Devices program overwhelmingly supported Impulse Dynamics NV's Optimizer Smart system, an implant that delivers cardiac contractility modulation to patients with heart failure. The recommendation came despite panel uncertainty during a Dec. 4 meeting as to whether there was enough trial data to prove safety and effectiveness. See what Bram Zuckerman, the director of FDA's division of cardiovascular devices, said about it here. 

“You may disagree with the methodology, and the sponsor may need to explain how the exchangeability worked, but a key tenet of this [Breakthrough] pathway is that sponsors can propose new methodology to show safety and effectiveness.” –Bram Zuckerman, director, FDA division of cardiovascular devices

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts